Benuvia Manufacturing Names Two Cannabinoid Industry Experts to Senior Advisory Board and Promotes Jim Mitchell to Vice President

These leaders in the cannabinoid industry are set to strategically advise Benuvia Manufacturing, a growing, privately held company.

ROUND ROCK, TEXAS. April 28, 2021 – Benuvia Manufacturing, Inc, a leading CDMO providing small molecule active pharmaceutical ingredients, formulation and drug product manufacturing from preclinical to commercial scale, announces the appointment of two cannabinoid industry experts to its Senior Advisory Board.  The new members of the Board bring more than a unique expertise with over 40 years of experience.

Jahan Marcu, PhD and Nigam B. Arora, PhD join four other industry experts on the Benuvia Manufacturing Board. Both Drs. Marcu and Arora are experts in the cannabinoid field as it relates to research, policy and operations.

“The addition of Dr. Marcu and Dr. Arora further advances the reach of Benuvia Manufacturing’s cannabinoid manufacturing and formulation capabilities.” Said Jim Mitchell, newly named Vice President, API Research and Development.  “This is an enabling move allowing us to get these molecular tools into the hands of the investigators and patients needing them most.” Mitchell’s promotion was announced on April 15th.

Dr. Marcu has 20 years of experience in cannabinoid research, policy, and operations.  His work has been instrumental to facilitating and supporting fact-based, scientific approaches vital to industry and patients.  This has included research focused on solving the structure and function of cannabinoid receptors, the anti-cancer properties of cannabis compounds, as well as method development and validation for analyzing complex formulations.   Dr. Marcu is a Founding Partner at the consulting firm of Marcu & Arora. He is presently the Editor-In-Chief of the American Journal of Endocannabinoid Medicine. He is also co-founder and past-chair of the Cannabis Chemistry Subdivision of the American Chemical Society (ACS), the world’s largest and oldest professional scientific society.

“I’m excited to be working with a Schedule 1 licensed drug manufacturer that is eager to apply their data to address issues facing the production of safe products.” Dr. Marcu said.

Dr. Arora has a long history of success working in translational research, business, and advocacy.  He is a Founding Partner at Marcu & Arora, a life science consulting firm focused on cannabis and psychedelics.  Dr. Arora completed his PhD in interdisciplinary life science with a focus on organic and analytical chemistry at Purdue University.  Over the past several years Dr. Arora has dedicated his time to working on the executive teams of several cannabis companies as well as serving as the Publication Committee Chair of the Cannabis Chemistry Subdivision of the American Chemical Society. He also has deep experience in advocacy including advocating for formation of the cannabis research license category in Massachusetts in 2018, serving on the policy committee of the Humboldt County Growers Alliance in California in 2019, and serving as a Sam H. Jones Community Service Scholar.

According to Dr. Arora, “I look forward to working with a company that is ready to tackle the future of drug manufacturing in the cannabinoid space and beyond.  Benuvia Manufacturing’s alignment with cGMP standards and their active positioning to accommodate federal regulations that are sure to come is very promising.”

Benuvia Manufacturing Commercial Operations

Benuvia Manufacturing operates over 83,000 square feet of state-of-the-art research, development, and manufacturing space in its cGMP facility located in Round Rock, Texas. The manufacturing facility received its Type II Drug Master File  (32552) from the U.S. Food and Drug Administration (FDA) in 2014 to produce pharmaceutical grade pure quality cannabidiol. Today, Round Rock is the only CBD active pharmaceutical ingredient (API) contract manufacturing site in the U.S. producing an FDA approved pharmaceutical cannabinoid drug. The facility is a DEA and FDA registered production site and is fully regulated and compliant with DEA, EPA, and OSHA requirements.

Benuvia Manufacturing also manufacturers SYNDROS® (dronabinol), a prescription medicine approved by the FDA for the treatment of  nausea and vomiting caused by anti-cancer medicine (chemotherapy) in patients who have failed to respond adequately to conventional antiemetic treatments and anorexia associated weight loss in patients with AIDS (Acquired Immune Deficiency Syndrome).

Benuvia Manufacturing offers a comprehensive suite of solutions for pharmaceutical, biotechnology, and consumer product companies to achieve their development and commercial needs:

  • Drug product manufacturing and small molecule active pharmaceutical ingredient non-cGMP and cGMP from grams to commercial metric ton scale
  • Preclinical and clinical drug product formulations
  • Quality assurance and validation
  • Analytical services
  • Drug development including custom synthesis
  • Serialization

About Benuvia Manufacturing, Inc.
Benuvia Manufacturing, Inc. is a privately held contract manufacturing organization that develops and manufactures active pharmaceutical ingredients and products. For more information visit www.benuviamanufacturing.com.

For Press Inquiries, please contact:

Molly Stone

205-365-3005

mstone@benuvia.com